Search Results

Drug Development

Peptilogics Reports Positive 180-Day Top-Line Interim Data From Phase 1B Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

Peptilogics, a clinical-stage biotechnology company, today announced new top-line interim data for PLG0206 in periprosthetic joint infection (PJI) patients from their ongoing Phase 1b trial.

September 19, 2023

·

6 min read

Drug Development

Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial.

May 24, 2023

·

5 min read

Business

Peptilogics Strengthens Leadership Team with Executive Appointments

Peptilogics today announced two executive appointments to strengthen and expand its leadership team.

August 10, 2022

·

6 min read

Pharm Country

Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)

Peptilogics announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections on Monday, February 27, 2023 at 11 AM ET.

February 21, 2023

·

3 min read

Business

EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership

EpiAxis Therapeutics and Peptilogics announced today that they have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.

August 15, 2022

·

3 min read

Pharm Country

Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

Peptilogics is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at ID Week 2022.

October 20, 2022

·

5 min read

Drug Development

Peptilogics Completes Phase 1b Trial Enrollment & Will Present Interim Top-line Safety & Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023

Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention for treatment of a Periprosthetic Joint Infection occurring after Total Knee Arthroplasty.

April 6, 2023

·

4 min read

Pharm Country

Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh

Peptilogics will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.

August 2, 2022

·

5 min read

Drug Development

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

October 7, 2022

·

4 min read

Drug Development

Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 trial for the treatment of periprosthetic joint infections (PJI) occurring after a total knee arthroplasty (TKA).

October 6, 2022

·

5 min read